(Q44189939)

English

Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.

scientific article published on 30 June 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 November 2017

Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. (English)

1 reference

Europe PubMed Central

30 November 2017

1

object named as

P Ljungman

1 reference

Europe PubMed Central

30 November 2017

author name string

R de la Camara

2

1 reference

Europe PubMed Central

30 November 2017

C Cordonnier

3

1 reference

Europe PubMed Central

30 November 2017

H Einsele

4

1 reference

Europe PubMed Central

30 November 2017

D Engelhard

5

1 reference

Europe PubMed Central

30 November 2017

P Reusser

6

1 reference

Europe PubMed Central

30 November 2017

J Styczynski

7

1 reference

Europe PubMed Central

30 November 2017

K Ward

8

1 reference

Europe PubMed Central

30 November 2017

European Conference on Infections in Leukemia

9

1 reference

Europe PubMed Central

30 November 2017

language of work or name

0 references

publication date

30 June 2008

1 reference

Europe PubMed Central

30 November 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

30 November 2017

42

1 reference

Europe PubMed Central

30 November 2017

4

1 reference

Europe PubMed Central

30 November 2017

227-240

1 reference

Europe PubMed Central

30 November 2017

https://scigraph.springernature.com/pub.10.1038/bmt.2008.162

0 references

Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Cytomegalovirus pneumonia in adult nontransplantation patients with cancer: review of 20 cases occurring from 1964 through 1990.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Cytomegalovirus pneumonia in adults with leukemia: an emerging problem

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Definitions of cytomegalovirus infection and disease in transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Evidence-based recommendations for the use of WBC-reduced cellular blood components

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Viral dynamics during active cytomegalovirus infection and pathology

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Evaluation of the COBAS Amplicor HCMV Monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Guidelines on the diagnosis and management of chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Cytomegaloviremia after autografting for leukemia: clinical significance and lack of effect on engraftment

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Cytomegalovirus (CMV)-Specific Intravenous Immunoglobulin for the Prevention of Primary CMV Infection and Disease after Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

CMV retinitis after allogeneic bone marrow transplantation: a report of five cases

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Treatment of Interstitial Pneumonitis Due to Cytomegalovirus with Ganciclovir and Intravenous Immune Globulin: Experience of European Bone Marrow Transplant Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Quantitative detection and differentiation of human herpesvirus 6 subtypes in bone marrow transplant patients by using a single real-time polymerase chain reaction assay.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Suppressive effects of human herpesvirus-6 on thrombopoietin-inducible megakaryocytic colony formation in vitro

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Human herpesvirus (HHV)-6 and HHV-7: two closely related viruses with different infection profiles in stem cell transplantation recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Three cases of human herpesvirus-6 latent infection: integration of viral genome in peripheral blood mononuclear cell DNA.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of human peripheral blood mononuclear cells in vivo

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Human herpesvirus 6 (HHV-6) is transmitted from parent to child in an integrated form and characterization of cases with chromosomally integrated HHV-6 DNA.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Transmission of integrated human herpesvirus 6 through stem cell transplantation: implications for laboratory diagnosis.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Human herpesvirus 6 chromosomal integration in immunocompetent patients results in high levels of viral DNA in blood, sera, and hair follicles

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Human herpesvirus 6 DNA levels in cerebrospinal fluid due to primary infection differ from those due to chromosomal viral integration and have implications for diagnosis of encephalitis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Evaluation of the specificity and sensitivity of indirect immunofluorescence tests for IgG to human herpesviruses-6 and -7.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Avidity of IgG antibodies to human herpesvirus-6 distinguishes primary from recurrent infection in organ transplant recipients and excludes cross-reactivity with other herpesviruses

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Human herpesvirus 6 and central nervous system disease in hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Human herpesvirus-6 infection in solid organ and stem cell transplant recipients.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Antiviral prophylaxis may prevent human herpesvirus-6 reactivation in bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Human herpesviruses-6 and -7 each cause significant neurological morbidity in Britain and Ireland

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Human herpesvirus 7 in pediatric hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Case report: human herpesvirus 7 associated fatal encephalitis in a peripheral blood stem cell transplant recipient

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Human herpesvirus-7 infection of the CNS with acute myelitis in an adult bone marrow recipient

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Human herpesvirus 7-associated meningitis and optic neuritis in a patient after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Transmission of human herpesvirus 8 by blood transfusion.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Bone marrow failure associated with human herpesvirus 8 infection after transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

CMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Failure of multiple antivirals to affect high HHV-6 DNAaemia resulting from viral chromosomal integration in case of severe aplastic anaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Disappearance of pre-existing high HHV-6 DNA load in blood after allogeneic SCT

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

21 January 2018

Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitation of cytomegalovirus: methodologic aspects and clinical applications.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab: prophylaxis vs. pre-emptive strategies for prevention

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infecti

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of human herpesvirus-6 as a causal agent for exanthem subitum

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Suppressive effects of human herpesvirus 6 on in vitro colony formation of hematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Unexpected occasional persistence of high levels of HHV-6 DNA in sera: detection of variants A and B

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Human herpesvirus-6 antigenemia after liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Human herpesvirus 7: another causal agent for roseola (exanthem subitum)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical manifestations associated with human herpesvirus 7 infection

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Human herpesvirus-6 and human herpesvirus-7 infections in bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Kaposi's sarcoma after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow failure associated with herpesvirus 8 infection in a patient undergoing autologous peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.162

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2008.162

1 reference

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44189939&oldid=2151127667"